ARUP's Laboratory Test Directory
| 0092209: inv(16) for AML(CBFB-MYH11) by RT-PCR |
| Test Mnemonic: INV(16) | |
|
Methodology: Reverse Transcription Polymerase Chain Reaction
Performed: Varies Reported: 4-7 days |
| Specimen Required: | |
|
Collect: One 5 mL lavender (EDTA) or pink (K2EDTA), or 3 mL bone marrow (EDTA).
Transport: 3 mL whole blood (EDTA) or bone marrow (EDTA) at 2-8°C. (Min: 1 mL) Remarks: Samples must be received within 48 hours of collection due to lability of RNA. Stability: Ambient: 4 hours; Refrigerated: 48 hours; Frozen: Unacceptable |
|
| Reference Interval: |
| By report |
| Interpretive Data: | |
|
Refer to report.
Please refer to Statement B in the Compliance Statements section in the front of the Laboratory Test Directory. |
| Note: | |
| CBFB (core binding factor b-chain)-MYH11 (myosin heavy chain 11 gene) fusion transcripts are detected in approximately 10% of de novo acute myelogenous leukemias (AML). One half of these cases belong to AML subtype M4 with abnormal eosinophils (AML-M4Eo). The fusion results from a pericentric inversion on chromosome 16 inv(16)(p13q22) or rarely from the translocation t(16;16)(p13;q22). Based on the breakpoints in the CBFB and MYH11 genes, greater than 95% of analyzed inv(16) cases belong to three types: A (88%), D (5%), and E (5%). |
| CPT Code(s): | |
| 83891 Isolation; 83902 Reverse transcription; 83913 RNA stabilization; 83898 x5 Amplification; 83894 x3 Gel separation; 83912 Interpretation and report - Additional CPT code modifiers may be required for procedures performed to test for oncologic or inherited disorders. |